Breakthrough in heart failure with preserved ejection fraction: are we there yet?

The Korean Journal of Internal Medicine
Shir Lynn Lim, Carolyn S P Lam

Abstract

Heart failure with preserved ejection fraction (HFPEF) is a global health problem of considerable socioeconomic burden. It is projected to worsen with the aging population worldwide. The lack of effective therapies underscores our incomplete understanding of this complex heterogeneous syndrome. A novel paradigm has recently emerged, in which central roles are ascribed to systemic inflammation and generalized endothelial dysfunction in the pathophysiology of HFPEF. In this review, we discuss the role of the endothelium in cardiovascular homeostasis and how deranged endothelial-related signaling pathways contribute to the development of HFPEF. We also review the novel therapies in various stages of research and development that target different components of this signaling pathway.

References

May 1, 1994·Circulation Research·A M ShahE G Lakatta
May 28, 1993·Biochemical and Biophysical Research Communications·D B McNamaraD L Akers
Mar 15, 1996·Circulation·P MohanS U Sys
Mar 10, 2001·Nature·J P StaschM Schramm
Jun 9, 2001·Arteriosclerosis, Thrombosis, and Vascular Biology·L K HeilbronnP M Clifton
Aug 8, 2001·Circulation·B I LevyH A Struijker-Boudier
Oct 5, 2002·Hypertension·Agostino VirdisErnesto L Schiffrin
Nov 28, 2002·Diabetes·Michelle G WallisMichael G Clark
Jun 9, 2004·Autonomic Neuroscience : Basic & Clinical·Catherine Sweeney, Farouk Markos
Jun 24, 2004·American Journal of Physiology. Heart and Circulatory Physiology·Walter J Paulus, Jean G F Bronzwaer
Nov 10, 2004·The New England Journal of Medicine·Anne L TaylorUNKNOWN African-American Heart Failure Trial Investigators
Feb 9, 2005·Circulation·Attila BorbélyWalter J Paulus
Aug 24, 2005·Antioxidants & Redox Signaling·David Sanz-RosaVicente Lahera
Apr 19, 2006·Circulation·Loek van HeerebeekWalter J Paulus
May 3, 2006·Circulation·Liliana R V CastroRodolphe Fischmeister
Jul 21, 2006·The New England Journal of Medicine·R Sacha BhatiaPeter P Liu
Sep 7, 2006·Nature Reviews. Drug Discovery·Oleg V EvgenovJohannes-Peter Stasch
Sep 12, 2006·European Heart Journal·John G F ClelandUNKNOWN PEP-CHF Investigators
Oct 5, 2006·The Journal of Clinical Endocrinology and Metabolism·Elena De FilippisLawrence J Mandarino

❮ Previous
Next ❯

Citations

Aug 23, 2018·Journal of Cellular Physiology·Xiaochen HeJian-Xiong Chen
Feb 15, 2019·The Korean Journal of Internal Medicine·JinShil KimMi-Seung Shin
May 22, 2018·The Korean Journal of Internal Medicine·Takahiro OkumuraToyoaki Murohara
May 24, 2020·Journal of Cardiovascular Translational Research·Elise L KesslerSaskia C A de Jager
Feb 24, 2021·Cardiovascular Research·Guillermo Luxán, Stefanie Dimmeler

❮ Previous
Next ❯

Methods Mentioned

BETA
biopsies

Clinical Trials Mentioned

NCT01599117
NCT01516346
NCT01920711
NCT00662116
NCT01014572

Software Mentioned

- PRESERVED
SOCRATES
TOPCAT

Related Concepts

Related Feeds

Aging-Associated Metabolic Disorders

Age is associated with many metabolic disorders including cardiovascular diseases, type 2 diabetes, stroke and heart disease. The mediators in aging process have been suggested to play a part in the cellular processes responsible for these metabolic disorders. Here is the latest research on aging-associated metabolic disorders.

Cardiovascular Inflammation

Inflammation plays a significant role in the development of cardiovascular diseases, an understanding of these endogenous processes is critical for evaluating the risks and potential treatment strategies. Discover the latest research on cardiovascular inflammation here.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.